Organisms | Evidence |
---|---|
Pseudomonas aeruginosa | |
Macaca mulatta (Rhesus monkey) | |
Toxocara canis (dog roundworm) | |
Drosophila melanogaster (fruit fly) | |
Caenorhabditis elegans |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
---|---|---|---|---|
ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GALNAC2 | CMP-Neu5Ac |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr |
Pathway Name | Organism |
---|---|
E.coli O101 | Escherichia coli |
E.coli O103 | Escherichia coli |
E.coli O107 | Escherichia coli |
E.coli O112ab | Escherichia coli |
E.coli O112ac | Escherichia coli |
E.coli O116 | Escherichia coli |
E.coli O117 | Escherichia coli |
E.coli O125ab | Escherichia coli |
E.coli O127 | Escherichia coli |
E.coli O128ab-H27 | Escherichia coli |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
33928571 | siRNA Design and GalNAc-Empowered Hepatic Targeted Delivery | Lu M | 2021 |
|
33928572 | Synthesis of GalNAc-Oligonucleotide Conjugates Using GalNAc Phosphoramidite and Triple-GalNAc CPG Solid Support | Ulashchik EA | 2021 |
|
32989128 | Metabolic precision labeling enables selective probing of O-linked N -acetylgalactosamine glycosylation | Debets MF | 2020 Sep 28 |
|
32819592 | Structural and biochemical analyses of β-N-acetylhexosaminidase Am0868 from Akkermansia muciniphila involved in mucin degradation | Xu W | 2020 Sep 03 |
|
32580089 | RETRACTED: Radiosynthesis and biological evaluation of fluorine-18 labeled N-acetylgalactosamine derivative [18F]FPGalNAc for PET imaging of asialoglycoprotein receptor-positive tumors | Sun P | 2020 Sep |
|
33043761 | Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP) | Massachi S | 2020 Oct 27 |
|
32936032 | Lectin recognition and hepatocyte endocytosis of GalNAc-decorated nanostructured lipid carriers | Gauthier L | 2020 Oct 02 |
|
33176091 | Givosiran for Acute Intermittent Porphyria. Reply | Gomá-Garcés E | 2020 Nov 12 |
|
33149259 | Characterisation of the main PSA glycoforms in aggressive prostate cancer | Gratacós-Mulleras A | 2020 Nov 04 |
|
32342633 | Synthesis and Structural Analysis of Aspergillus fumigatus Galactosaminogalactans Featuring α‐Galactose, α‐Galactosamine and α‐N‐Acetyl Galactosamine Linkages | Zhang Y | 2020 May 20 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025